Roll-out in approved European countries is ongoing.


Swiss regulatory authorities has given Debiopharm’s therapy for sexual deviations the go-ahead. Initial discussions with potential marketing partners for Switzerland are in progress.

The injectable GnRH agonist analogue, Moapar®, is indicated for use once every three months in the reversible reduction of serum testosterone in men diagnosed with this disdorder. Used in combination with psychotherapy, it cuts serum testosterone down to castration levels.

The treatment was recently launched in Germany and Belgium as Salvacyl®. It is also sanctioned in France, the U.K., Sweden, Norway, Denmark, The Netherlands, and Finland via the European Mutual Recognition Procedure. Debiopharm says that the drug will be launched progressively in European countries by its commercial partners during 2009 and 2010. 

The company claims clinical trials have shown Salvacyl/Moapar has fewer side effects than antiandrogens, including a lower risk of hepatocellular damage, thromboembolism, and gynecomastia.

 

 








This site uses Akismet to reduce spam. Learn how your comment data is processed.